Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

A startup seeking to replace animal testing with a sophisticated high-tech platform has raised $40 million to develop ...

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...

A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, ...